Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.19 USD
-0.01 (-5.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.19 USD
-0.01 (-5.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone bio (GRTS) delivered earnings and revenue surprises of 38.46% and 66.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -45.60% and 8.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of 75% and 150.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 175.68% and 47.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -25% and 9.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
by Zacks Equity Research
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Gritstone bio (GRTS) stock based on the movements in the options market lately.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -1.49% and 37.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 6.25% and 38.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.